Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stewart Gold Rush
Galore Resources arranges $267,750 private placement
2009-10-23 20:02 ET - News Release
Mr. Michael Byrne reports
GALORE ANNOUNCES A PRIVATE PLACEMENT
Galore Resources Inc. is arranging a $267,750 non-brokered private placement through the sale of 1,164,136 flow-through units at a price of 23 cents per flow-through unit. Each flow-through unit will consist of one flow-through common share and one non-flow-through share purchase warrant. Each warrant will be exercisable into one common share for a period of two years from closing of the financing at a price of 33 cents per share. The financing is subject to regulatory approval.
There are no commissions being paid or agent options being issued on this placement.
From this offering, the company will raise approximately $267,750. Proceeds will be used to further drill test Galore's 100-per-cent-owned Taseko gold, copper and molybdenum property located 20 kilometres south of the Taseko mines' Prosperity project in southwestern British Columbia.
We seek Safe Harbor.
Smart slime.
He's quite a history alright. It's amazing the number of deals this guy gets involved with.
You ever follow Allana (Stan Bharti)?
GALORE EXPANDS DRILL PROGRAM AT DOS SANTOS
Vancouver, BC, Galore Resources Inc. (GRI-TSX.V) announces that it is expanding from ten to 13
holes on the drilling program at the San Jose epithermal gold target on its Dos Santos property in
Zacatecas State, Mexico. The 14,000-hectare Dos Santos property is located adjacent to the northern
claim boundary of Canplats Resources’ Camino Rojo gold-silver-lead-zinc discovery.
Assay results for the first ten holes on the Dos Santos project are expected in approximately three weeks.
Galore will release results from the first ten holes after these assays have been received and confirmed by
check assays of sample duplicates sent to a second laboratory. Assays from holes ten to 13 will follow.
Galore’s Reverse Circulation (RC) drill program continues to explore the San Jose epithermal gold target,
where numerous carbonate-iron oxide veins on surface returned gold analyses of up to 208 gm/tonne over
0.5 metres. The drill is currently on hole 11 and the 3,500 metre drill program is near completion. The
program began by testing the limits of a one-kilometer-diameter alteration zone, and progressively tested
mineralized structures towards a central structural zone. Mechanical problems have caused a series of
delays, which have slowed the data flow.
Earlier in 2009, an eight-week exploration program confirmed that an overburden-covered area in the
southern part of the property is underlain by the Caracol Formation, the host to the Camino Rojo and
Penasquito gold deposits. Limited outcrops and waste dumps from excavations also contained altered
varieties of the Caracol which returned anomalous geochemical concentrations of gold, arsenic, lead and
zinc. Gold concentrations range from 11 to 61 ppb gold. Drill testing to date has focused on more
advanced targets within the Dos Santos property; but Galore intends to aggressively explore this southern
area as it considers the target to be highly prospective for the Camino Rojo-style gold-silver-lead-zinc
mineralization.
Octavio Gonzalez, Galore’s Vice-President Exploration for Mexico, manages the Dos Santos exploration
program. Uwe Schmidt, P.Geo., Vice-President Exploration and Galore’s Qualified Person as defined by
Canada’s National Instrument 43-101, supervises the Dos Santos program and has verified the technical
data in this release.
Galore Resources is a British Columbia-based exploration company that has assembled a leading group of
industry professionals to acquire and explore for promising deposits with an emphasis on gold in Mexico
and base metals in the Taseko Lakes region of southwestern British Columbia. To find out more about
Galore Resources (TSX.V:GRI) please visit our website at www.galoreresources.com .
GALORE RESOURCES INC.
“Michael W. Byrne”
President
PharmaGap Announces Completion of Securities Lending Arrangements with Stormont
Last Update: 10/21/2009 9:28:59 AM
OTTAWA, ONTARIO, Oct 21, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") today advises that the Securities Lending Agreements ("SLA") between SC Stormont Holdings Inc. ("Stormont") and subscribers to the 5,387,000 PharmaGap Equity Units issued on June 17, 2009 (the "Private Placement") have been satisfied in full.
Pursuant to these arrangements, Stormont committed to lend up to 13,125,000 freely trading common shares of PharmaGap held by it to subscribers in the Private Placement, repayable by the subscriber to Stormont in the form of freely tradable shares on the conclusion of the 4 month hold period on October 19, 2009. The total amount made available by Stormont included common shares issued directly and for issuance if all warrants in the Private Placement were exercised.
The effect of the SLAs was to restrict sale of shares held by Stormont for four months and to allow subscribers for equity units from treasury of PharmaGap to trade an equal number of common shares received from Stormont. This agreement was put in place after consulting with the TSX Venture Exchange.
Since June 17, 2009, a total of 6,757,060 common shares were lent to subscribers by Stormont, and were reported by Stormont as dispositions in the market in regulatory filings. These 6,757,060 common shares have now been repaid to Stormont, and will accordingly be reflected in regulatory filings as an acquisition of shares, as prescribed.
Mr. Rod Bryden, Chairman of both PharmaGap and Stormont, stated that "I am very pleased that I was in a position to enable PharmaGap to complete the issuance of shares and warrants in very difficult market conditions by adding the incentive of freely trading shares, by restricting sale of shares held by my company Stormont . I have full confidence in PharmaGap, as shown over the past 4 years of my involvement, and the confirmatory testing so far at the U.S. National Cancer Institute and at the Ottawa Hospital Research Institute has supported that confidence. I am less happy that I have had to reduce my holdings in PharmaGap recently, however this has been necessitated in order to meet obligations of Stormont originally entered into to provide funding to PharmaGap."
An additional 1,139,095 shares were made available to subscribers of 717,000 PharmaGap Equity Units issued on July 16, 2009 by Stormont in a second closing of the Private Placement under further SLA. These shares are scheduled to be returned to Stormont on November 19, 2009
About SC Stormont Holdings Inc.
SC Stormont Holdings Inc. is a holding company principally owned by Roderick M. Bryden, which currently holds 20,692,493 Common Shares, (23.1%) of PharmaGap and is PharmaGap's largest shareholder.
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
PharmaGap Announces Completion of Securities Lending Arrangements with Stormont
Last Update: 10/21/2009 9:28:59 AM
OTTAWA, ONTARIO, Oct 21, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") today advises that the Securities Lending Agreements ("SLA") between SC Stormont Holdings Inc. ("Stormont") and subscribers to the 5,387,000 PharmaGap Equity Units issued on June 17, 2009 (the "Private Placement") have been satisfied in full.
Pursuant to these arrangements, Stormont committed to lend up to 13,125,000 freely trading common shares of PharmaGap held by it to subscribers in the Private Placement, repayable by the subscriber to Stormont in the form of freely tradable shares on the conclusion of the 4 month hold period on October 19, 2009. The total amount made available by Stormont included common shares issued directly and for issuance if all warrants in the Private Placement were exercised.
The effect of the SLAs was to restrict sale of shares held by Stormont for four months and to allow subscribers for equity units from treasury of PharmaGap to trade an equal number of common shares received from Stormont. This agreement was put in place after consulting with the TSX Venture Exchange.
Since June 17, 2009, a total of 6,757,060 common shares were lent to subscribers by Stormont, and were reported by Stormont as dispositions in the market in regulatory filings. These 6,757,060 common shares have now been repaid to Stormont, and will accordingly be reflected in regulatory filings as an acquisition of shares, as prescribed.
Mr. Rod Bryden, Chairman of both PharmaGap and Stormont, stated that "I am very pleased that I was in a position to enable PharmaGap to complete the issuance of shares and warrants in very difficult market conditions by adding the incentive of freely trading shares, by restricting sale of shares held by my company Stormont . I have full confidence in PharmaGap, as shown over the past 4 years of my involvement, and the confirmatory testing so far at the U.S. National Cancer Institute and at the Ottawa Hospital Research Institute has supported that confidence. I am less happy that I have had to reduce my holdings in PharmaGap recently, however this has been necessitated in order to meet obligations of Stormont originally entered into to provide funding to PharmaGap."
An additional 1,139,095 shares were made available to subscribers of 717,000 PharmaGap Equity Units issued on July 16, 2009 by Stormont in a second closing of the Private Placement under further SLA. These shares are scheduled to be returned to Stormont on November 19, 2009
About SC Stormont Holdings Inc.
SC Stormont Holdings Inc. is a holding company principally owned by Roderick M. Bryden, which currently holds 20,692,493 Common Shares, (23.1%) of PharmaGap and is PharmaGap's largest shareholder.
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
PharmaGap Advises That NCI Test Results Are Completed and Expected to Be Provided to the Company Shortly
Last Update: 10/20/2009 11:05:59 AM
OTTAWA, ONTARIO, Oct 20, 2009 (MARKETWIRE via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") advises that the results of dose-range testing of the Company's cancer drug GAP-107B8 at the United States National Cancer Institute ("NCI") can be expected "shortly". NCI staff has indicated to the Company that testing has been completed and the results can be expected to be received by the Company after analysis and review of these results by the NCI has been completed.
The Company announced the results from single dose testing at the NCI on August 24, 2009, which showed significant inhibition of cancer cell growth at a low drug concentration across a wide range of human cancer cells. In this initial single dose test, GAP107B8 demonstrated greater than 50% inhibition in cancer cell growth in 26 of 57 cell lines tested, across all 9 cancer types included in the test panel. The full release can be found on the Company's website.
The NCI dose range test repeats the single dose test at 5 different dose concentrations across the same cell lines, in order to provide further insights into the drug's activity at low dose concentrations. With this data, the PharmaGap drug can be compared with the estimated 40,000 drug compounds in the NCI database, using the NCI's COMPARE software programs, enabling NCI and Company researchers to further understand the drug's mechanism of action against defined pathways associated with specific cancer types, in order to better define the target cancer or cancers for which application for clinical trials will be made.
Mr. Robert McInnis, President and C.E.O. of PharmaGap, stated that "while we had expected to have the results of this testing in hand earlier, the NCI has indicated that their analysis of the data is proceeding in normal course and will be released to us when that analysis is completed"
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
Contacts:
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
SOURCE: PharmaGap Inc.
mailto:bmcinnis@pharmagap.com
Copyright 2009 Marketwire, Inc., All rights reserved.
PharmaGap Advises That NCI Test Results Are Completed and Expected to Be Provided to the Company Shortly
Last Update: 10/20/2009 11:05:59 AM
OTTAWA, ONTARIO, Oct 20, 2009 (MARKETWIRE via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") advises that the results of dose-range testing of the Company's cancer drug GAP-107B8 at the United States National Cancer Institute ("NCI") can be expected "shortly". NCI staff has indicated to the Company that testing has been completed and the results can be expected to be received by the Company after analysis and review of these results by the NCI has been completed.
The Company announced the results from single dose testing at the NCI on August 24, 2009, which showed significant inhibition of cancer cell growth at a low drug concentration across a wide range of human cancer cells. In this initial single dose test, GAP107B8 demonstrated greater than 50% inhibition in cancer cell growth in 26 of 57 cell lines tested, across all 9 cancer types included in the test panel. The full release can be found on the Company's website.
The NCI dose range test repeats the single dose test at 5 different dose concentrations across the same cell lines, in order to provide further insights into the drug's activity at low dose concentrations. With this data, the PharmaGap drug can be compared with the estimated 40,000 drug compounds in the NCI database, using the NCI's COMPARE software programs, enabling NCI and Company researchers to further understand the drug's mechanism of action against defined pathways associated with specific cancer types, in order to better define the target cancer or cancers for which application for clinical trials will be made.
Mr. Robert McInnis, President and C.E.O. of PharmaGap, stated that "while we had expected to have the results of this testing in hand earlier, the NCI has indicated that their analysis of the data is proceeding in normal course and will be released to us when that analysis is completed"
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
Contacts:
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
SOURCE: PharmaGap Inc.
mailto:bmcinnis@pharmagap.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Odd trading on GRI for sure. One insider buying but really crazy buying. Drives the price up once a week by taking out all the asks. Strange stuff.
TIM
Following GRI ? Insider buying. Property in a good area.
GRI
Growing POT again are you?
Bon Voyage!
Nice trend - Trina Solar
GAP 5-dose test results from NCI should be coming out this week or next.
Winter has come too early
Haven't won the lottery yet.
Picked up some GRI at the close.
Pharmagap should have 5-dose test results from the NCI for its pre-clinical cancer drug GAP-107B8 later this week. Pharmagap trades on the TSXV under the symbol GAP and on the OTCBB under the symbol PHRGF.
I think he is referring to the stock with the symbol CAN
Canaco drills 53 m of 4.32 g/t Au at Magambazi
You missed a hell of a game!
Next Time maybe... Have a great weekend!!!
Elk Island at 8:38
I was thinking Legends but they are booked. Too many peeps around here.
Guess so. I'm golfing tomorrow AM I think. Let me know if you feel like a drive.
Good show over all. Some new material I didn't know and a few songs I would have liked to hear but didn't (Locked in the trunk of a car) (38 years old). I saw a few Oilers in the crowd.
Gord went through a lot of handkerchiefs.
Opti unaware of reasons for share price jump
2009-09-17 11:51 ET - News Release
An anonymous director reports
OPTI CANADA COMMENTS ON TRADING ACTIVITY
Opti Canada Inc. is not aware of any specific circumstances that may be contributing to the recent increase in market price and the level of trading activity of its shares. Opti commented on the recent and unusual trading in the stock at the request of market surveillance on behalf of the Toronto Stock Exchange.
We seek Safe Harbor.
OPC
Let me look into my crystal ball.
Ottawa Hospital Research Institute Testing of PharmaGap’s Novel Cancer Drug Formally Underway
Ottawa, Ontario/September 17, 2009 – PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) (“PharmaGap” or “the Company”) is pleased to announce that Dr. Barbara Vanderhyden of the Ottawa Hospital Research Institute (“OHRI”) is proceeding with an expanded testing program for the Company’s lead cancer drug GAP-107B8. Dr. Vanderhyden is a senior cancer researcher at the OHRI with a specialized focus on ovarian cancer. She recently completed successful testing of GAP-107B8 in nine human ovarian cancer cell lines, as was announced by the Company on August 6, 2009.
Dr. Vanderhyden and her colleagues are now expanding their testing of GAP-107B8, using mouse models of human ovarian cancer. The initial phases of testing are focused on dosing range, routes of drug administration and cancer tumour targeting. Data gathered will be incorporated into studies assessing the drug’s effect on slowing cancer progression and reducing tumour burden. Results of this testing program are anticipated over the next two quarters.
Robert C. McInnis, President and C.E.O. of PharmaGap said “We are pleased that the OHRI has elected to proceed with testing of GAP-107B8. Data generated by Dr. Vanderhyden in this study, along with the data generated at the U.S. National Cancer Institute (“NCI”), will provide key independently derived information to our Clinical Advisory Group as they guide our drug toward application to commence human clinical trials.”
According to the NCI, ovarian cancer will affect over 22,000 women this year in the U.S. and over 14,000 will die. The five-year survival rate for ovarian cancer is under 30%.
Dr. Barbara Vanderhyden is a Senior Scientist, Cancer Therapeutics at the OHRI and a Professor in the Departments of Cellular & Molecular Medicine and Obstetrics & Gynecology at the University of Ottawa. She holds the Corinne Boyer Chair in Ovarian Cancer Research. She has published over 60 peer reviewed journal papers primarily in the area of ovarian cancer and collaborates extensively with many pharmaceutical and biotechnology companies focused on the development of therapies for ovarian cancer.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with the University’s Faculties of Medicine and Health Sciences. The OHRI includes more than 1,300 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. For more information please visit www.ohri.ca.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development and targets PKC alpha. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.
For information relating to this Release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com
Note: The TSX-Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
GAP is the next CVM
How was the vacation?